

Journal of Visualized Experiments

Isolating, sequencing and analyzing extracellular microRNAs from human mesenchymal stem cells

--Manuscript Draft--

Article Type:	Invited Methods Article - JoVE Produced Video
Manuscript Number:	JoVE58655R2
Full Title:	Isolating, sequencing and analyzing extracellular microRNAs from human mesenchymal stem cells
Keywords:	Mesenchymal Stem Cells, extracellular RNAs, exosomes, extracellular vesicles, ribonucleoproteins, microRNAs, small RNAs, next generation sequencing, small RNA library construction
Corresponding Author:	Chi-Chih Chang Aarhus Universitet Århus C, Denmark DENMARK
Corresponding Author's Institution:	Aarhus Universitet
Corresponding Author E-Mail:	chang@inano.au.dk
Order of Authors:	Chi-Chih Chang Yan Yan Morten T Venø Colin R Mothershead Junyi Su Jørgen Kjems
Additional Information:	
Question	Response
Please indicate whether this article will be Standard Access or Open Access.	Standard Access (US\$2,400)
Please indicate the city, state/province, and country where this article will be filmed . Please do not use abbreviations.	Copenhagen, Denmark



**INTERDISCIPLINARY
NANOSCIENCE CENTER**
FACULTY OF SCIENCE
AARHUS UNIVERSITY

Dear Dr. Nandita Singh,
We hereby re-submit our manuscript entitled

“Isolating, sequencing and analyzing extracellular microRNAs from human mesenchymal stem cells” by Yan Yan, Chi-Chih Chang, Morten T Venø, Colin R Mothershead, Junyi Su and Jørgen Kjems to be evaluated for publication in JoVE.

None of the material presented in this manuscript has been or is under consideration for publication elsewhere. The manuscript has been seen and approved by all listed authors. Furthermore, we declare no conflict of interests.

In our protocol, we detailed the steps for small RNA library construction (particularly for microRNAs) from low input samples such as cell culture media. Important quality control steps are enclosed, which will be useful for authors working towards profiling extracellular RNAs. We believe the protocol is highly relevant, especially for the emerging research and importance of extracellular and circulating RNAs. We therefore believe this protocol would be of interest to the broad audience of your journal.

Best wishes

Jørgen Kjems
Professor and Chair of Interdisciplinary Nanoscience Center (iNANO)

**Interdisciplinary
Nanoscience Center**

Jørgen Kjems

Professor
Head of iNANO

Date: 22 June 2018

Direct Tel.: +45 89422686

Mobile Tel.: +45 28992086

Fax: +45 8619 6500

E-mail: kjems@inano.au.dk

Web: www.inano.dk

TITLE:

Isolating, Sequencing and Analyzing Extracellular MicroRNAs From Human Mesenchymal Stem Cells

AUTHORS AND AFFILIATIONS:

Yan Yan^{1,*}, Chi-Chih Chang^{1,*}, Morten T Venø^{1,2}, Colin R Mothershead¹, Junyi Su¹, Jørgen Kjems^{1,2}

¹The Interdisciplinary Nanoscience Centre, Aarhus University, Aarhus, Denmark

²Department of Molecular Biology and Genetics, Aarhus University, Aarhus, Denmark

*These authors contributed equally.

Corresponding Author:

Jørgen Kjems (jk@mbg.au.dk)

Email Addresses of Co-authors:

Yan Yan (yanyan@inano.au.dk)

Chi-Chih Chang (chang@inano.au.dk)

Morten Venø (mtv@mbg.au.dk)

Colin Mothershead (colin.mothershead@inano.au.dk)

Junyi Su (junyi@inano.au.dk)

KEYWORDS:

mesenchymal stem cells, extracellular RNAs, exosomes, extracellular vesicles, ribonucleoproteins, microRNAs, small RNAs, next generation sequencing, small RNA library construction

SUMMARY:

This protocol demonstrates how to purify extracellular microRNAs from cell culture media for small RNA library construction and next generation sequencing. Various quality control checkpoints are described to allow readers to understand what to expect when working with low input samples like exRNAs.

ABSTRACT:

Extracellular and circulating RNAs (exRNA) are produced by many cell types of the body and exist in numerous bodily fluids such as saliva, plasma, serum, milk and urine. One subset of these RNAs are the posttranscriptional regulators – microRNAs (miRNAs). To delineate the miRNAs produced by specific cell types, in vitro culture systems can be used to harvest and profile exRNAs derived from one subset of cells. The secreted factors of mesenchymal stem cells are implicated in alleviating numerous diseases and is used as the in vitro model system here. This paper describes the process of collection, purification of small RNA and library generation to sequence extracellular miRNAs. ExRNAs from culture media differ from cellular RNA by being low RNA input samples, which calls for optimized procedures. This protocol provides a comprehensive guide to small exRNA sequencing from culture media, showing quality control checkpoints at each step during exRNA purification and sequencing.

INTRODUCTION:

Extracellular and circulating RNAs (exRNAs) are present in various bodily fluids and are resistant towards RNases^{1,2}. Their high abundance, stability and ease of accessibility are attractive for clinical assessment as diagnostic and prognostic markers³. The mode of transport for exRNAs include extracellular vesicles (EVs), association with lipoproteins (such as high-density lipoprotein; HDL) and ribonucleoprotein complexes (such as with Argonaute2 complexes)⁴.

A subset of exRNAs are microRNAs (miRNAs), which are small non-coding RNAs of about 22 nt that regulate posttranscriptional gene expression. Ex-miRNAs have been implicated in cell-cell communication and regulation of cell homeostasis⁵. For example, HDL delivers ex-miR-223 to endothelial cells to repress intercellular adhesion molecule 1 (ICAM-1) and inflammation⁶. Interestingly, miR-223 is also seen transported by extracellular vesicles from leukocytes to lung cancer cells, programming them to take on a more invasive phenotype⁷. Thus, the transcriptome of ex-miRNAs from various bodily fluids and cell culture medium will greatly improve our understanding of ex-miRNA signaling.

Small RNA sequencing (small RNA seq) is a powerful tool that can be used to understand the transcriptomics of small RNAs. Not only can different samples be compared amongst differentially expressed known RNAs, but novel small RNAs can also be detected and characterized. Consequently, it is also a robust method to identify differentially expressed miRNAs under different conditions. However, one of the hurdles of small RNA seq is the difficulty in generating small RNA seq libraries from low exRNA input fluids like cerebrospinal fluids, saliva, urine, milk, serum and culture media. The TruSeq Small RNA Library Prep protocol from Illumina requires approximately 1 µg of high quality total RNA and the NEBNext Small RNA Library Prep Set protocol from New England Biolabs requires 100 ng-1 µg of RNA^{8,9}. Oftentimes, total RNA from these samples are below detection limit for conventional UV-vis spectrophotometers.

Ex-miRNAs derived from bodily fluids are potentially good prognostic and diagnostic markers. However, in order to study the functional effects or to determine the origin of specific ex-miRNAs, cell culture systems are often used instead. Mesenchymal stem cells (MSCs) have been studied extensively because their EVs have been implicated in alleviating many diseases including myocardial infarction, Alzheimer's disease and graft versus host disease¹⁰. Here, we demonstrate the purification of ex-miRNAs from bone marrow-derived MSCs (BMSCs) and the specific steps used to optimize small RNA library construction, sequencing and data analysis (**Figure 1**).

PROTOCOL:

NOTE: Mesenchymal stem cell growth medium (MSC media) is prepared beforehand as indicated in the **Table of Materials**.

1. Cell culture

NOTE: Human mesenchymal stem cells can be obtained from the bone marrow, adipose tissue or other sources¹¹. Alternatively, hMSCs can be bought through a supplier. The BMSCs used in this protocol were derived from the bone marrow of patients and bought from a company.

1.1 Thaw 1×10^6 BMSCs into a T175 flask containing 20 mL of MSC media. Incubate the cells at 37 °C with 5% CO₂ and replace the media every 2-3 days until 80% confluency.

1.2 Wash the cells with 5 mL of 1x PBS and discard the PBS.

1.3 Detach the cells by adding 5 mL of 0.05% Trypsin-EDTA and incubating the cells for 5 min at 37 °C. Tap the sides of the flask to facilitate detachment.

1.4 Add 15 mL of MSC media to inactivate the trypsin, detach the cells from the surface, and pipette up and down to obtain single cell suspensions.

1.5 Collect the cells in a 50 mL tube and spin down for 5 min at 300 x *g* to pellet the cells.

1.6 Resuspend the cells in 1 mL of MSC media and count the cells using a hemocytometer.

NOTE: Primary human bone marrow MSCs at 80% confluency in a T175 flask is around 2×10^6 cells.

1.7 Plate hMSCs at 2,000 cells/cm² in fresh MSC media in 5 T175 flasks. Grow the cells at 37 °C with 5% CO₂ and replace the media every 2-3 days until 5 flasks of 90% confluent T175 flasks are obtained.

2. EVs and RNA-associated biomolecules collection

NOTE: EV collection media is prepared beforehand (Dulbecco's Modified Eagle's Medium [DMEM] with 10% fetal bovine serum [FBS] and 1% penicillin/streptomycin [P/S]). EV collection media is normal MSC media, but prepared with commercial EV-depleted FBS (**Table of Materials**). This is to avoid bovine exRNA contamination from FBS, which normally contains exRNAs associated with EVs, ribonucleoproteins, and lipoproteins. For small RNA library preparation, exRNAs derived from 5 confluent flasks of MSCs are required to enable library construction.

2.1 Wash the cells 3x with 20 mL of PBS per T175 flask. Add 20 mL of EV collection media per confluent T175 flask of MSCs and incubate at 37 °C with 5% CO₂ for 48 h.

2.2 Collect the media and centrifuge the media for 10 min at 300 x *g* and 4 °C.

2.3 Collect the supernatant and centrifuge the media for 20 min at 2,000 x *g* and 4 °C.

2.4 Collect the supernatant and centrifuge the media for 30 min at 15,500 x *g* and 4 °C. Then collect the supernatant.

2.5 Transfer the media to ultracentrifuge tubes and pellet the exRNAs for 90 min at 100,000 x *g* and 4 °C. The pellet is anchored to the side of the tube, which is visible, brown and transparent.

2.6 Remove the supernatant, dry the inside of the tube by inverting the tube on absorbent paper and use small pieces of absorbent paper to remove the liquid inside the tube without touching the bottom of the tube. Resuspend the pellet in 200 µL of PBS by vortexing for 30 s and pipetting up and down 20x.

2.7 Assess the EVs and biomolecules with nanoparticle tracking analysis (NTA) (**Figure 2**).

NOTE: The EVs and biomolecules can be assessed with nanoparticle tracking analysis (NTA), dynamic light scattering (DLS) or transmission electron microscopy (TEM)¹².

2.8 Store the EVs and biomolecules at -80 °C until further downstream experiments.

NOTE: If EVs are going to be used for functional studies, 20% glycerol must be added to protect them from rupturing. The cells can be collected using standard procedures if necessary.

3. EVs and RNA-associated biomolecules collection of differentiated cells

NOTE: EVs and RNA associated biomolecules can also be collected from the cell culture media while the cells undergo differentiation. The example depicted in the protocol describes osteoblastic differentiation and exRNA collection at day 0 and 7 of differentiation. If no differentiation is required, then skip Section 3 and go to Section 4.

3.1 Prepare osteoblastic differentiation media (DMEM with 10% FBS, 1% P/S, 10 mM β-glycerophosphate, 10 nM dexamethasone, 50 µM ascorbate-2-phosphate, and 10 mM 1.25-vitamin-D3) fresh every time.

3.2 Once MSCs are 80% confluent, change the MSC media to osteoblastic differentiation media.

3.3 Replenish the osteoblastic differentiation media after 2-3 days.

3.4 On day 5 of differentiation, remove the media and wash the cells 3x with 20 mL of PBS per T175 flask.

3.5 Add 20 mL of EV collection media containing 10 mM β-glycerophosphate, 10 nM dexamethasone, 50 µM ascorbate-2-phosphate and 10 mM 1.25-vitamin-D₃ per confluent T175 flask of MSCs. Incubate the cells at 37 °C with 5% CO₂ for 48 h to ensure continued differentiation while collecting the EVs and biomolecules.

3.6 Collect the media on Day 7 and proceed to isolate the EVs and biomolecules as described in steps 2.2-2.6.

3.7 For quality control, seed cells in 96-wells or 6-wells to assess differentiation using an alkaline phosphatase (ALP) activity assay or with quantitative polymerase chain reaction (qPCR), respectively.

NOTE: **Figure 3** is an example showing osteogenic differentiation of the cells.

4. RNA extraction and quality control

4.1 Thaw samples from step 2.8 on ice. Extract RNA using an RNA isolation kit (**Table of Materials**).

4.2 Elute the RNA from the column provided in the RNA isolation kit (**Table of Materials**) in 100 μ L of RNase-free water.

4.3 Concentrate the RNA through ethanol precipitation by adding 1 μ L of glycogen, 10 μ L of 2 M pH 5.5 sodium acetate and 250 μ L of pre-chilled 99% ethanol into 100 μ L of purified RNA.

4.4 Incubate the samples at -20 °C overnight to precipitate the RNA. Pellet the RNA by centrifuging for 20 min at 16,000 x *g* and 4 °C.

NOTE: The pellet is white due to co-precipitation with glycogen.

4.5 Remove the supernatant and wash the RNA pellet with 1 mL of 75% ethanol. Pellet the RNA again for 5 min at 16,000 x *g* and 4 °C.

4.6 Remove the ethanol and leave the lid of the RNA tube open for 5-10 min to air dry the RNA pellet. Resuspend the RNA pellet in 7 μ L of RNase-free water.

4.7 Check the RNA quality and concentration using a chip-based capillary electrophoresis machine to detect the RNA according to the manufacturer's protocol prior to library construction.

NOTE: A representative size distribution of the RNA is shown in **Figure 4**.

4.8 Extract cellular RNA using a commercial purification kit (**Table of Materials**) if necessary.

5. Library construction and quality control

NOTE: Small RNA libraries are constructed using commercial kits (**Table of Materials**) with adjustments due to the low RNA input. Library construction is performed on the chilled block.

219 5.1 Chill the heating block for 0.2 mL PCR tubes on ice and pipette 5 μ L of the RNA from step
220 4.6 into 0.2 mL RNase-free PCR tubes on a chilled block.

221
222 5.2 Dilute 3' adaptors (1:10) in RNase-free water in a 0.2 mL RNase-free PCR tube. Add 0.5 μ L
223 of diluted adaptor and mix with 5 μ L of RNA by pipetting up and down 8x and centrifuge briefly
224 to collect all the liquid at the bottom of the tube.

225
226 5.3 Incubate the RNA and 3' adaptor mix at 70 $^{\circ}$ C for 2 min in a preheated thermal cycler and
227 then place the sample back on the chilled block.

228
229 5.4 Add 1 μ L of ligation buffer, 0.5 μ L of RNase inhibitor, and 0.5 μ L of T4 RNA ligase (deletion
230 mutant) into the RNA and 3' adaptor mixture. Mix by pipetting up and down 8x and centrifuge
231 briefly.

232
233 5.5 Incubate the tube at 28 $^{\circ}$ C for 1 h in the preheated thermal cycler.

234
235 5.6 Add 0.5 μ L of stop solution into the sample tube with the tube staying in the thermal
236 cycler, mix by pipetting up and down 8x and continue to incubate at 28 $^{\circ}$ C for 15 min.

237
238 5.7 Dilute 5' adaptors (1:10) in RNase-free water in a 0.2 mL RNase-free PCR tube. Add 0.5 μ L
239 of 5' adaptor into a separate RNase-free 0.2 mL PCR tube, heat the 5' adaptor at 70 $^{\circ}$ C for 2 min
240 in the preheated thermal cycler, and then place the sample on the chilled block.

241
242 5.8 Add 0.5 μ L of 10 nM ATP, 0.5 μ L of T4 RNA ligase to the 5' adaptor tube, mix by pipetting
243 up and down 8x and centrifuge briefly to collect all the liquids into the bottom.

244
245 NOTE: Keep the 5' adaptor on chilled block as much as possible.

246
247 5.9 Add 1.5 μ L of the 5' adaptor mixture to the sample from step 5.6, and mix very gently by
248 pipetting 8x slowly. Incubate the sample at 28 $^{\circ}$ C for 1 h in the preheated thermal cycler.

249
250 5.10 Dilute RT primer 1:10 in RNase-free water in an RNase-free 0.2 mL PCR tube. Add 0.5 μ L
251 of diluted RT primer into the sample from step 5.9, mix very gently by pipetting up and down 8x
252 slowly and centrifuge briefly.

253
254 5.11 Incubate the sample at 70 $^{\circ}$ C for 2 min in the preheated thermal cycler and then place the
255 sample on a chilled block.

256
257 5.12 Add 1 μ L of 5x first strand buffer, 0.5 μ L of 12.5 mM dNTP mix, 0.5 μ L of 100 mM
258 dithiothreitol (DTT), 0.5 μ L of RNase inhibitor, and 0.5 μ L of reverse transcriptase. Mix very gently
259 by pipetting up and down 8x slowly and centrifuge briefly.

260
261 5.13 Incubate the sample at 50 $^{\circ}$ C for 1 h in the preheated thermal cycler to obtain cDNA.
262

5.14 Add 4.25 μ L of ultrapure water, 12.5 μ L of PCR mix, 1 μ L of index primer, and 1 μ L of universal primer into the cDNA. Mix by pipetting up and down 8x and centrifuge briefly.

5.15 Place the sample in a thermal cycler and set up the cycler as follows: 98 $^{\circ}$ C for 30 s; 15 cycles of 98 $^{\circ}$ C for 10 s, 60 $^{\circ}$ C for 30 s and 72 $^{\circ}$ C for 15 s; and end the cycle with 72 $^{\circ}$ C for 10 min.

NOTE: The prepared library can be stored at -20 $^{\circ}$ C for one week.

5.16 Purify the RNA library by separating the library on a DNA gel and cutting the gel (gel extraction) between 140 bp and 160 bp and eluting the library from the gel following the protocol given by the library construction kit.

NOTE: In this study, the prepared library from step 5.15 is loaded onto a commercial gel (**Table of Materials**) and the library between 140 bp and 160 bp is purified out by an automated DNA size fractionator (**Table of Materials**) according to the manufacturer's protocol.

5.17 Concentrate and wash the library from step 5.16 using a column-based PCR purification kit (**Table of Materials**) and elute the library in 10 μ L RNase-free water finally.

5.18 Load 1 μ L of the purified library onto a DNA chip (**Table of Materials**) to check the size of the library following the manufacturer's protocol.

5.19 Dilute 1 μ L of the purified library (1:1000) in 10 mM pH 8.0 Tris-HCl with 0.05% polysorbate 20 and quantify the library by qPCR using a commercial library quantification kit to quantify the library concentration using the DNA standards in the kit.

5.20 Pool equal amounts of the libraries according to the requirements of the sequencing machine and sequence on a high-throughput sequencing system.

NOTE: The library construction of cellular RNA can be done using the same kits by following standard protocol of the kits.

6. Bioinformatics pipeline

NOTE: This is an in-house pipeline and the programs used here are listed in the **Table of Materials**.

6.1 Trim away low-quality reads and remove adaptor sequences from the raw reads.

6.2 Map the clean reads to different kinds of RNAs.

6.2.1 Annotate tRNAs by allowing two mismatches because the heavily modified tRNA sequences cause frequent base misincorporation by reverse transcriptase.

6.2.2 Annotate miRNAs by mapping to human miRNAs from miRBase v21 allowing zero mismatches. Since miRNAs are subject to A and U nontemplated 3' end additions, sequences that do not map are 3' trimmed of up to three A and/or T nts after which reads are mapped to human miRNAs and other miRNAs from miRBase v21 allowing zero mismatches.

6.2.3 Annotate to other relevant small RNAs (snRNA, snoRNA, piRNA, and Y RNAs) by allowing one mismatch.

6.2.4 Map the remaining unmapped reads to long RNA datasets (rRNA, other RNA from Rfam, and mRNA) to assess degradation.

6.2.5 Annotate the sequences to the human genome.

6.2.6 Annotate the sequences to bacterial genomes.

6.2.7 Normalize miRNA expression using the following formula: miRNA counts / the total counts of all mapped miRNAs) x 10^6 .

REPRESENTATIVE RESULTS:

The method described in this protocol is optimized to collect exRNA from MSC culture for next generation sequencing. The overall scheme of the workflow is in **Figure 1** on the left and the respective quality control checkpoints are on the right.

The morphology of the cells on the day of collection for undifferentiated (**Figure 3A**) and differentiated (**Figure 3B**) cells are shown. Furthermore, representative normalized levels of ALP activity of cells induced for 7 days are also shown (**Figure 3C**). Here, ALP activity is approximately 2.5 times that of the uninduced cells.

Three T175 flasks of confluent MSCs yield $2-5 \times 10^{10}$ particles/mL (**Figure 2**). Mean particle size is approximately 160-165 nm while most of the particles are 130-140 nm. There were a few smaller peaks between 200 and 500 nm, which would indicate large complexes or large aggregates.

Since RNA can be degraded quickly, adhere strictly to the conditions of RNA extraction as per the kit or protocol used. Use RNase-free conditions, in particular RNase-free water to resuspend the RNA and keep RNA on ice when possible. After extraction, the RNA can be quantified using a chip-based capillary electrophoresis machine. Representative electropherograms of the RNA after being analyzed are shown in **Figure 4**. The electropherogram of exRNAs includes a broad range of RNAs (**Figure 4A**). In contrast, cellular RNA has very distinct peaks at around 70-120, 1800, and 3800 nt, which correspond to tRNA/5S rRNA/5.8S rRNA, 18S rRNA, and 28S rRNA, respectively (**Figure 4B**). The RNA integrity number (RIN) represents the quality of the RNA. A good RIN of cellular RNA is >8 (indicating almost no RNA degradation). The algorithm on which RIN is based is the ratio between 28S and 18S. This means that RIN is not a good indicator of RNA quality of exRNAs because full-length rRNAs are usually not detectable in exRNAs.

Following RNA extraction, the miRNA libraries were constructed and the cDNA libraries were separated by gel electrophoresis. The adaptor-ligated cDNA of the miRNAs is typically between 140 and 160 nt. The quality of the library was then visualized on a chip-based capillary electrophoresis machine (**Figure 5**). **Figure 5A** and **Figure 5B** are the libraries from the cellular RNA at Day 0 and Day 7, respectively. **Figures 5C** and **Figure 5D** are the exRNA libraries at Day 0 and Day 7 respectively. All four samples had peaks at around 140 nt, which indicate successful miRNA library construction. The amount of cDNA in the libraries was quantified by qPCR using a library quantification kit. The quantification cycle (C_q) of the standards was plotted against the log of the concentration to obtain a standard curve (**Figure 6**). The equation of the standard curve was then used to calculate the concentration of the libraries (**Table 1**). In our sample, the concentration of the libraries from exRNAs was 5-8 nM, which was significantly lower than libraries from cellular RNAs (8-30 nM). The libraries were then pooled with equal amount and sent for sequencing.

After the libraries were sequenced, the low-quality reads were trimmed away with FASTX-Toolkit and the resulting quality of the library exRNAs was high and comparable to that of the libraries from the cells (**Figure 7A,B**). The sequence length of the libraries from cells had a single peak at around 22 nt (**Figure 7C**), which correlates with miRNAs. In contrast, the libraries from exRNAs were more heterogeneous and contained 3 major peaks: 22 nt, 30 nt, and 33 nt (**Figure 7D**). Similar to their cellular counterparts, the peak at 22 nt is the miRNAs. Closer inspection revealed that the peaks at 30 and 33 nt are tRNAs halves/fragments or piRNAs. The annotations of the mapped reads were then plotted. Most of the reads (65.1%) from cellular RNA mapped to human miRNAs and each of the other small RNAs accounted for a small portion of the mapped reads (**Figure 8A**). Contrastingly, only 8% of exRNAs mapped to human miRNAs (**Figure 8B**). The most abundant small RNA to which the reads mapped were tRNAs. Most of the reads were “unmatched reads” (43%). Further examination of the unmatched reads from exRNAs to global databases led to the surprising finding that most of them correspond to bacterial sequences (74% and 85% for D0 and D7 exRNA, respectively; **Table 2**). In contrast, only 0.9% of the cellular RNA was unmatched and, of those, only 10% mapped to bacteria. A comparison to the bovine genome showed less than 1% match suggesting that FBS was not a source of contamination (**Table 2**). Hence, exRNAs exhibit an atypical profile compared to normal cellular RNA.

FIGURE AND TABLE LEGENDS:

Figure 1: Workflow of exRNA sequencing and analysis. The entire workflow is depicted on the left in the grey boxes and quality control associated with each step is in the red boxes on the right.

Figure 2: Size distribution of particles secreted by the cells at day 0 and day 7 of differentiation. Representative NTA results of particles collected from 3 x T175 flasks at (A) Day 0 and (B) Day 7 of differentiation. The respective mean and mode sizes as well as the concentration of the particles are tabulated beneath the graphs. SD: standard deviation.

Figure 3: Cell morphology and osteogenic differentiation prior to extracellular RNA collection. (A) Micrograph of undifferentiated BMSCs cultured with collection media on the day of collection.

(B) Micrograph of BMSCs differentiated for 7 days with collection media on the day of collection. Scale bars = 100 μ m. (C) ALP Activities of the cells were normalized to their respective cell viabilities. The values plotted were that of three independent experiments.

Figure 4: Representative electropherogram of RNA integrity after RNA extraction. RNA analyses of extracellular RNA (A) and cellular RNA (B). The x-axis is the length of the RNA (nt) and the y-axis is the fluorescence. The first peak is the ladder at 25 nt. Ribosomal RNAs are shown as 18S (1,800 nt) and 28S (3,800 nt). RNA integrity number (RIN) is an indicator of RNA quality based on the 18S and 28S ribosomal RNA integrity. Higher RIN numbers equal better quality.

Figure 5: Representative electropherogram of the cDNA libraries after library construction. DNA analyses of the libraries from (A) cells at Day 0, (B) cells at Day 7, (C) extracellular RNA from Day 0, and (D) extracellular RNA from Day 7. Green and purple numbers are the ladders at 35 nt and 10,380 nt, respectively.

Figure 6: cDNA library quantification and calculation. Libraries were diluted between 500-1,000 times for those from exRNA and between 1,000 and 4,000 times for cell RNA. The libraries were run alongside the standards from the library quantification kit. The average Cq values of the DNA standards were plotted against the \log_{10} concentration (pM) to generate a standard curve, an equation for the standard curve and an R^2 value.

Figure 7: Quality scores and length distribution of sequences. Low quality reads and adaptor sequences were trimmed with FASTX-Toolkit for (A) cells and (B) exRNAs. The length distribution of clean reads for (C) cells and (D) exRNAs.

Figure 8: Annotation of small RNAs after sequencing. Annotations represent percentages of clean reads for (A) cells and (B) exRNAs.

Table 1: miRNA library quantification.

Table 2: The percentage of unmatched reads that map to bacteria and bovine reads.

DISCUSSION:

Here, we describe a protocol for next generation sequencing of exRNAs that enables differential expression analyses from low input samples. Adhering to a specific protocol for EV and exRNA isolation is important because even small alterations (i.e., the ultracentrifugation step or a change in rotor type) can influence the transcriptome and miRNA levels^{13,14}. Thus, regardless of how the exRNA is isolated, it is important to apply the same experimental and bioinformatic procedure to all the samples in an experiment to be able to compare the results.

RNA integrity is usually assessed on the bioanalyzer. However, since exRNAs are devoid of full length rRNA, their RIN value is very low, but this does not necessarily reflect low quality RNA samples. Additionally, the RNA concentration of the exRNAs varied greatly and is often inaccurate. Hence, instead of assessing RNA quality and quantifying the RNA on the bioanalyzer, use the

same volume of media each time for further processing. Also, resuspend the extracted RNA in the same volume of resuspension buffer and use the same volume for library construction.

Small RNA library construction was optimized by reducing the amount of adaptors to a tenth of the standard protocol and using one-half of the other reagents. Reducing the adaptors not only prevents adaptor dimers, it also prevents intramolecular RNA circularization¹⁵. The reduction in reagents is optimized for the Illumina TruSeq Small RNA Sample Prep Kit. Should other kits be used, it is recommended to also lower adaptor and reagents accordingly, unless the kit specifies that it is tailored to low input samples. Finally, the PCR cycle for library construction was increased from 12 to 15 cycles in this protocol to account for the low concentration of exRNAs. We have found this to be the optimal adjustment without seeing amplification biases¹⁵.

Various quality control metrics can be assessed including base quality scores and read length profile. When doing bioinformatics analyses, the base quality of the reads in cellular RNA and exRNAs were similar; however, the length distribution and the annotated origin of sequences were completely different. Most of the reads from cellular RNA mapped to human miRNAs, however, a large proportion of the exRNA reads were unmatched reads. Upon closer inspection, the unmatched reads turned out to be bacterial reads (**Table 2**). This was surprising because antibiotics were routinely used in our culture. Our result aligns well with other reports that also showed large proportion of unmatched reads when sequencing cell culture derived exRNA¹⁶. One of the reasons for these contaminants is that bacteria overlap in size with extracellular complexes or EVs, and hence co-purify during the ultracentrifugation step¹⁷. Previous publications have identified widespread contamination of certain bacteria in culture media which remain undetected under normal cell lab procedures¹⁸. To date, this problem has largely been ignored but should be taken into account when purifying and analyzing exRNAs.

This protocol details a complete guide to harvesting exRNAs from culture media, optimizing small RNA library preparation and processing the raw library data. This protocol specifically highlights the various quality control checkpoints throughout the process to demonstrate how low input samples (like exRNAs) can deviate from normal sample preparations so that others working with low input samples may know what to expect.

ACKNOWLEDGMENTS:

We are grateful to Mr. Claus Bus and Ms. Rita Rosendahl at iNANO for their technical assistance. Special thanks to Dr. Daniel Otzen for allowing our frequent use of his ultracentrifuge. This study was supported by the Innovation Fund Denmark (MUSTER project).


DISCLOSURES:

The authors have nothing to disclose.


REFERENCES:

- 1 Etheridge, A., Gomes, C.P., Pereira, R.W., Galas, D., Wang, K. The complexity, function and applications of RNA in circulation. *Frontiers in Genetics*. **4**, 115, doi:10.3389/fgene.2013.00115 (2013).

- 2 Koberle, V. et al. Differential Stability of Cell-Free Circulating microRNAs: Implications for
Their Utilization as Biomarkers. *Plos One*. **8** (9), doi:ARTN e75184
10.1371/journal.pone.0075184 (2013).
- 3 Anfossi, S., Babayan, A., Pantel, K., Calin, G.A. Clinical utility of circulating non-coding
RNAs - an update. *Nature Reviews Clinical Oncology*. doi:10.1038/s41571-018-0035-x (2018).
- 4 Li, K. et al. Advances, challenges, and opportunities in extracellular RNA biology: insights
from the NIH exRNA Strategic Workshop. *JCI Insight*. **3** (7), doi:10.1172/jci.insight.98942 (2018).
- 5 Turchinovich, A., Samatov, T.R., Tonevitsky, A.G., Burwinkel, B. Circulating miRNAs: cell-
cell communication function? *Frontiers in Genetics*. **4**, 119, doi:10.3389/fgene.2013.00119 (2013).
- 6 Tabet, F. et al. HDL-transferred microRNA-223 regulates ICAM-1 expression in endothelial
cells. *Nature Communications*. **5**, 3292, doi:10.1038/ncomms4292 (2014).
- 7 Zangari, J. et al. Rapid decay of engulfed extracellular miRNA by XRN1 exonuclease
promotes transient epithelial-mesenchymal transition. *Nucleic Acids Research*. **45** (7), 4131-4141,
doi:10.1093/nar/gkw1284 (2017).
- 8 Illumina. *TruSeq RNA Sample Prep Kit v2 Support Input Requirements*.
[https://support.illumina.com/sequencing/sequencing_kits/truseq_rna_sample_prep_kit_v2/in
put_req.html](https://support.illumina.com/sequencing/sequencing_kits/truseq_rna_sample_prep_kit_v2/input_req.html) Accessed on: 28 May 2018, (2018).
- 9 NEB. NEBNext Multiplex Small RNA Library Prep Set for Illumina Set 1, Set 2, Index
Primers 1–48 and Multiplex Compatible Instruction Manual. Retrieved from
[https://www.neb.com/-/media/catalog/datacards-or-
manuals/manuale7300_e7330_e7560_e7580.pdf](https://www.neb.com/-/media/catalog/datacards-or-manuals/manuale7300_e7330_e7560_e7580.pdf) (2018).
- 10 Heldring, N., Mager, I., Wood, M.J.A., Le Blanc, K., Andaloussi, S.E.L. Therapeutic Potential
of Multipotent Mesenchymal Stromal Cells and Their Extracellular Vesicles. *Human Gene Therapy*.
26 (8), 506-517, doi:10.1089/hum.2015.072 (2015).
- 11 Ullah, I., Subbarao, R.B., Rho, G.J. Human mesenchymal stem cells - current trends and
future prospective. *Bioscience Reports*. **35** (2), doi:10.1042/BSR20150025 (2015).
- 12 Szatanek, R. et al. The Methods of Choice for Extracellular Vesicles (EVs) Characterization.
International Journal of Molecular Sciences. **18** (6), doi:10.3390/ijms18061153 (2017).
- 13 Gardiner, C. et al. Techniques used for the isolation and characterization of extracellular
vesicles: results of a worldwide survey. *Journal of Extracellular Vesicles*. **5**, doi:UNSP 32945
10.3402/jev.v5.32945 (2016).
- 14 Van Deun, J. et al. EV-TRACK: transparent reporting and centralizing knowledge in
extracellular vesicle research. *Nature Methods*. **14** (3), 228-232 (2017).
- 15 Raabe, C.A., Tang, T.H., Brosius, J., Rozhdestvensky, T.S. Biases in small RNA deep
sequencing data. *Nucleic Acids Research*. **42** (3), 1414-1426, doi:10.1093/nar/gkt1021 (2014).
- 16 Reza, A.M., Choi, Y.J., Yasuda, H., Kim, J.H. Human adipose mesenchymal stem cell-
derived exosomal-miRNAs are critical factors for inducing anti-proliferation signalling to A2780
and SKOV-3 ovarian cancer cells. *Scientific Reports*. **6**, 38498, doi:10.1038/srep38498 (2016).
- 17 Gyorgy, B. et al. Membrane vesicles, current state-of-the-art: emerging role of
extracellular vesicles. *Cellular and Molecular Life Sciences*. **68** (16), 2667-2688,
doi:10.1007/s00018-011-0689-3 (2011).
- 18 Asghar, M.T. et al. Sphingomonas sp is a Novel Cell Culture Contaminant. *Journal of
Cellular Biochemistry*. **116** (6), 934-942, doi:10.1002/jcb.25044 (2015).




A. Representative NTA results from 3 x T175 flasks at D0




Mean: 161.7 ± 4.0 nm
Mode: 140.8 ± 6.3 nm
SD: 66.9 ± 8.4 nm
Concentration: $5.08 \times 10^{10} \pm 4.04 \times 10^9$ particles/mL


B. Representative NTA results from 3 x T175 flasks at D7




Mean: 165.9 ± 1.7 nm
Mode: 132.9 ± 6.6 nm
SD: 63.8 ± 6.5 nm
Concentration: $2.03 \times 10^{10} \pm 1.87 \times 10^9$ particles/mL



A. Media
RIN: 2.50



B. Cell
RIN: 8.40







Figure 6










Figure 8



Sample	Dilution factor	Cq value	log(pM)	Concentration (pM)	Concentration mean (pM)
BMSC D0 exRNA	500	7.72	0.702	5.036	5.276
BMSC D0 exRNA	500	7.57	0.754	5.677	
BMSC D0 exRNA	500	7.7	0.709	5.117	
BMSC D0 exRNA	1000	8.64	0.383	2.416	2.365
BMSC D0 exRNA	1000	8.68	0.369	2.340	
BMSC D0 exRNA	1000	8.68	0.369	2.340	
BMSC D7 exRNA	500	8.52	0.425	2.659	3.221
BMSC D7 exRNA	500	8.42	0.459	2.880	
BMSC D7 exRNA	500	7.97	0.615	4.125	
BMSC D7 exRNA	1000	8.87	0.303	2.011	1.933
BMSC D7 exRNA	1000	8.92	0.286	1.932	
BMSC D7 exRNA	1000	8.97	0.269	1.857	
BMSC D0 cell	1000	6.86	1.000	10.005	9.810
BMSC D0 cell	1000	6.91	0.983	9.614	
BMSC D0 cell	4000	8.68	0.369	2.340	2.398
BMSC D0 cell	4000	8.59	0.400	2.514	
BMSC D0 cell	4000	8.68	0.369	2.340	
BMSC D7 cell	1000	8.44	0.452	2.834	2.880
BMSC D7 cell	1000	8.43	0.456	2.857	
BMSC D7 cell	1000	8.39	0.470	2.950	
BMSC D7 cell	4000	10.36	-0.213	0.612	0.702
BMSC D7 cell	4000	10.27	-0.182	0.658	
BMSC D7 cell	4000	9.97	-0.078	0.836	

Calculations:

$\log(\text{pM}) = -0.3467 \times (\text{Sample Cq value}) + 3.3786$; use the standard curve and formula

$\text{concentration (pM)} = 10^{\log(\text{pM})}$

Size adjustment calculation = Size of DNA standard (452 bp) divided by the average fragment length

Concentration mean * (452/143)	Multiply by dillution factor (pM)
16.678	8338.993
7.477	7476.846
10.182	5090.913
6.110	6110.391
31.007	31006.974
7.581	30322.041
9.104	9104.439
2.218	8872.689

gth (143 bp)

Sample:	# reads not mapping human	# reads mapping to bacteria	% bacterial reads
BMSC D0 Cell	131007	9858	8%
BMSC D7 Cell	169730	7935	5%
BMSC D0 exRNA	6122833	4551477	74%
BMSC D7 exRNA	7046691	5970086	85%

# reads mapping to cow	% bovine reads
99	0.08%
188	0.11%
891	0.01%
771	0.01%

Name of Reagent/ Equipment	Company	Catalog Number
Bone Marrow-Derived Mesenchymal Stem Cells	ATCC	PCS-500-012
MSCGM BulletKit	Lonza	PT-3001
Exosome-depleted FBS	Gibco	A2720801
ExRNA collecting media: MSCGM but with the FBS replaced by exosome-depleted FBS		
Trypsin-EDTA	Gibco	25200056
T175 Flask	Sarstedt	833,912
Penicillin-Streptomycin	Gibco	15140122
Phosphate Buffered Saline	Sigma	806552
Ultracentrifuge	Beckman Coulter	
Polycarbonate Bottle with Cap Assembly	Beckman Coulter	355618
Beckman Coulter Type 60 Ti NucleoCounter	Chemometec	NC-3000
β -glycerophosphate	Calbiochem	35675
Dexamethasone	Sigma	D4902-25MG
2-Phospho-L-ascorbic acid trisodium ϵ	Sigma	49752-10G
1 α ,25-Dihydroxyvitamin D3	Sigma	D1530-1MG
miRNeasy Mini Kit	Qiagen	217004
Agilent RNA 6000 Pico Kit	Agilent Technologies	5067-1514
Agilent 2100 Bioanalyzer	Agilent Technologies	G2939BA
Agilent High Sensitivity DNA Kit	Agilent Technologies	5067-4626
KAPA Library Quantification Kits	Roche	KK4824
TruSeq Small RNA Library Prep Kit -S	Illumina	RS-200-0012
Pippin Prep	Sage Science	
MinElute PCR Purification Kit	Qiagen	28004
FASTX_Toolkit	Cold Spring Harbor Lab	
cutadapt		

Bowtie
Samtools
Bedtools

Comments/Description

Cells used in this protocol was bought from ATCC
Termed as Mesenchymal Stem Cell Growth Medium (MSC media)

Rotor used here
Cell Counter

Components of the osteogenic differentiation media

miRNA and total RNA purification kit for step 4.8

Chip-based capillary electrophoresis machine and chips for RNA and DNA
analysis

Library quantification kit used here

Small RNA library preparation kit used in this protocol - used in step 5

Automated DNA gel extractor used in this protocol; manual extraction can be done too
PCR purification in step 5.17

Trimming low-quality reads in step 6

Adaptor removal in step 6

Mapping of clean reads in step 6

To make the expression profile in step 6

To make the expression profile in step 6



1 Alewife Center #200
Cambridge, MA 02140
tel. 617.945.9051
www.jove.com

ARTICLE AND VIDEO LICENSE AGREEMENT

Title of Article: Isolating, sequencing and analyzing extracellular microRNAs from human mesenchymal stem cells

Author(s): Yan Yan, Chi-Chih Chang, Morten T Venø, Colin R Mothershead, Junyi Su, Jørgen Kjems

Item 1 (check one box): The Author elects to have the Materials be made available (as described at <http://www.jove.com/author>) via: ☒ Standard Access ☐ Open Access

Item 2 (check one box):

- ☒ The Author is NOT a United States government employee.
- ☐ The Author is a United States government employee and the Materials were prepared in the course of his or her duties as a United States government employee.
- ☐ The Author is a United States government employee but the Materials were NOT prepared in the course of his or her duties as a United States government employee.

ARTICLE AND VIDEO LICENSE AGREEMENT

1. **Defined Terms.** As used in this Article and Video License Agreement, the following terms shall have the following meanings: "**Agreement**" means this Article and Video License Agreement; "**Article**" means the article specified on the last page of this Agreement, including any associated materials such as texts, figures, tables, artwork, abstracts, or summaries contained therein; "**Author**" means the author who is a signatory to this Agreement; "**Collective Work**" means a work, such as a periodical issue, anthology or encyclopedia, in which the Materials in their entirety in unmodified form, along with a number of other contributions, constituting separate and independent works in themselves, are assembled into a collective whole; "**CRC License**" means the Creative Commons Attribution-Non Commercial-No Derivs 3.0 Unported Agreement, the terms and conditions of which can be found at: <http://creativecommons.org/licenses/by-nc-nd/3.0/legalcode>; "**Derivative Work**" means a work based upon the Materials or upon the Materials and other pre-existing works, such as a translation, musical arrangement, dramatization, fictionalization, motion picture version, sound recording, art reproduction, abridgment, condensation, or any other form in which the Materials may be recast, transformed, or adapted; "**Institution**" means the institution, listed on the last page of this Agreement, by which the Author was employed at the time of the creation of the Materials; "**JoVE**" means MyJoVE Corporation, a Massachusetts corporation and the publisher of *The Journal of Visualized Experiments*; "**Materials**" means the Article and / or the Video; "**Parties**" means the Author and JoVE; "**Video**" means any video(s) made by the Author, alone or in conjunction with any other parties, or by JoVE or its affiliates or agents, individually or in collaboration with the Author or any other parties, incorporating all or any portion of the Article, and in which the Author may or may not appear.

2. **Background.** The Author, who is the author of the Article, in order to ensure the dissemination and protection of the Article, desires to have the JoVE publish the Article and create and transmit videos based on the Article. In furtherance of such goals, the Parties desire to memorialize in this Agreement the respective rights of each Party in and to the Article and the Video.

3. **Grant of Rights in Article.** In consideration of JoVE agreeing to publish the Article, the Author hereby grants to JoVE, subject to Sections 4 and 7 below, the exclusive, royalty-free, perpetual (for the full term of copyright in the Article, including any extensions thereto) license (a) to publish, reproduce, distribute, display and store the Article in all forms, formats and media whether now known or hereafter developed (including without limitation in print, digital and electronic form) throughout the world, (b) to translate the Article into other languages, create adaptations, summaries or extracts of the Article or other Derivative Works (including, without limitation, the Video) or Collective Works based on all or any portion of the Article and exercise all of the rights set forth in (a) above in such translations, adaptations, summaries, extracts, Derivative Works or Collective Works and (c) to license others to do any or all of the above. The foregoing rights may be exercised in all media and formats, whether now known or hereafter devised, and include the right to make such modifications as are technically necessary to exercise the rights in other media and formats. If the "Open Access" box has been checked in Item 1 above, JoVE and the Author hereby grant to the public all such rights in the Article as provided in, but subject to all limitations and requirements set forth in, the CRC License.

ARTICLE AND VIDEO LICENSE AGREEMENT

4. **Retention of Rights in Article.** Notwithstanding the exclusive license granted to JoVE in **Section 3** above, the Author shall, with respect to the Article, retain the non-exclusive right to use all or part of the Article for the non-commercial purpose of giving lectures, presentations or teaching classes, and to post a copy of the Article on the Institution's website or the Author's personal website, in each case provided that a link to the Article on the JoVE website is provided and notice of JoVE's copyright in the Article is included. All non-copyright intellectual property rights in and to the Article, such as patent rights, shall remain with the Author.

5. **Grant of Rights in Video – Standard Access.** This **Section 5** applies if the "Standard Access" box has been checked in **Item 1** above or if no box has been checked in **Item 1** above. In consideration of JoVE agreeing to produce, display or otherwise assist with the Video, the Author hereby acknowledges and agrees that, Subject to **Section 7** below, JoVE is and shall be the sole and exclusive owner of all rights of any nature, including, without limitation, all copyrights, in and to the Video. To the extent that, by law, the Author is deemed, now or at any time in the future, to have any rights of any nature in or to the Video, the Author hereby disclaims all such rights and transfers all such rights to JoVE.

6. **Grant of Rights in Video – Open Access.** This **Section 6** applies only if the "Open Access" box has been checked in **Item 1** above. In consideration of JoVE agreeing to produce, display or otherwise assist with the Video, the Author hereby grants to JoVE, subject to **Section 7** below, the exclusive, royalty-free, perpetual (for the full term of copyright in the Article, including any extensions thereto) license (a) to publish, reproduce, distribute, display and store the Video in all forms, formats and media whether now known or hereafter developed (including without limitation in print, digital and electronic form) throughout the world, (b) to translate the Video into other languages, create adaptations, summaries or extracts of the Video or other Derivative Works or Collective Works based on all or any portion of the Video and exercise all of the rights set forth in (a) above in such translations, adaptations, summaries, extracts, Derivative Works or Collective Works and (c) to license others to do any or all of the above. The foregoing rights may be exercised in all media and formats, whether now known or hereafter devised, and include the right to make such modifications as are technically necessary to exercise the rights in other media and formats. For any Video to which this Section 6 is applicable, JoVE and the Author hereby grant to the public all such rights in the Video as provided in, but subject to all limitations and requirements set forth in, the CRC License.

7. **Government Employees.** If the Author is a United States government employee and the Article was prepared in the course of his or her duties as a United States government employee, as indicated in **Item 2** above, and any of the licenses or grants granted by the Author hereunder exceed the scope of the 17 U.S.C. 403, then the rights granted hereunder shall be limited to the maximum rights permitted under such

statute. In such case, all provisions contained herein that are not in conflict with such statute shall remain in full force and effect, and all provisions contained herein that do so conflict shall be deemed to be amended so as to provide to JoVE the maximum rights permissible within such statute.

8. **Likeness, Privacy, Personality.** The Author hereby grants JoVE the right to use the Author's name, voice, likeness, picture, photograph, image, biography and performance in any way, commercial or otherwise, in connection with the Materials and the sale, promotion and distribution thereof. The Author hereby waives any and all rights he or she may have, relating to his or her appearance in the Video or otherwise relating to the Materials, under all applicable privacy, likeness, personality or similar laws.

9. **Author Warranties.** The Author represents and warrants that the Article is original, that it has not been published, that the copyright interest is owned by the Author (or, if more than one author is listed at the beginning of this Agreement, by such authors collectively) and has not been assigned, licensed, or otherwise transferred to any other party. The Author represents and warrants that the author(s) listed at the top of this Agreement are the only authors of the Materials. If more than one author is listed at the top of this Agreement and if any such author has not entered into a separate Article and Video License Agreement with JoVE relating to the Materials, the Author represents and warrants that the Author has been authorized by each of the other such authors to execute this Agreement on his or her behalf and to bind him or her with respect to the terms of this Agreement as if each of them had been a party hereto as an Author. The Author warrants that the use, reproduction, distribution, public or private performance or display, and/or modification of all or any portion of the Materials does not and will not violate, infringe and/or misappropriate the patent, trademark, intellectual property or other rights of any third party. The Author represents and warrants that it has and will continue to comply with all government, institutional and other regulations, including, without limitation all institutional, laboratory, hospital, ethical, human and animal treatment, privacy, and all other rules, regulations, laws, procedures or guidelines, applicable to the Materials, and that all research involving human and animal subjects has been approved by the Author's relevant institutional review board.

10. **JoVE Discretion.** If the Author requests the assistance of JoVE in producing the Video in the Author's facility, the Author shall ensure that the presence of JoVE employees, agents or independent contractors is in accordance with the relevant regulations of the Author's institution. If more than one author is listed at the beginning of this Agreement, JoVE may, in its sole discretion, elect not take any action with respect to the Article until such time as it has received complete, executed Article and Video License Agreements from each such author. JoVE reserves the right, in its absolute and sole discretion and without giving any reason therefore, to accept or decline any work submitted to JoVE. JoVE and its employees, agents and independent contractors shall have

ARTICLE AND VIDEO LICENSE AGREEMENT

full, unfettered access to the facilities of the Author or of the Author's institution as necessary to make the Video, whether actually published or not. JoVE has sole discretion as to the method of making and publishing the Materials, including, without limitation, to all decisions regarding editing, lighting, filming, timing of publication, if any, length, quality, content and the like.

11. **Indemnification.** The Author agrees to indemnify JoVE and/or its successors and assigns from and against any and all claims, costs, and expenses, including attorney's fees, arising out of any breach of any warranty or other representations contained herein. The Author further agrees to indemnify and hold harmless JoVE from and against any and all claims, costs, and expenses, including attorney's fees, resulting from the breach by the Author of any representation or warranty contained herein or from allegations or instances of violation of intellectual property rights, damage to the Author's or the Author's institution's facilities, fraud, libel, defamation, research, equipment, experiments, property damage, personal injury, violations of institutional, laboratory, hospital, ethical, human and animal treatment, privacy or other rules, regulations, laws, procedures or guidelines, liabilities and other losses or damages related in any way to the submission of work to JoVE, making of videos by JoVE, or publication in JoVE or elsewhere by JoVE. The Author shall be responsible for, and shall hold JoVE harmless from, damages caused by lack of sterilization, lack of cleanliness or by contamination due to the making of a video by JoVE its employees, agents or independent contractors. All sterilization, cleanliness or decontamination procedures shall be solely the responsibility of the Author and shall be undertaken at the Author's


expense. All indemnifications provided herein shall include JoVE's attorney's fees and costs related to said losses or damages. Such indemnification and holding harmless shall include such losses or damages incurred by, or in connection with, acts or omissions of JoVE, its employees, agents or independent contractors.

12. **Fees.** To cover the cost incurred for publication, JoVE must receive payment before production and publication of the Materials. Payment is due in 21 days of invoice. Should the Materials not be published due to an editorial or production decision, these funds will be returned to the Author. Withdrawal by the Author of any submitted Materials after final peer review approval will result in a US\$1,200 fee to cover pre-production expenses incurred by JoVE. If payment is not received by the completion of filming, production and publication of the Materials will be suspended until payment is received.

13. **Transfer, Governing Law.** This Agreement may be assigned by JoVE and shall inure to the benefits of any of JoVE's successors and assignees. This Agreement shall be governed and construed by the internal laws of the Commonwealth of Massachusetts without giving effect to any conflict of law provision thereunder. This Agreement may be executed in counterparts, each of which shall be deemed an original, but all of which together shall be deemed to be one and the same agreement. A signed copy of this Agreement delivered by facsimile, e-mail or other means of electronic transmission shall be deemed to have the same legal effect as delivery of an original signed copy of this Agreement.

A signed copy of this document must be sent with all new submissions. Only one Agreement required per submission.

CORRESPONDING AUTHOR:

Name:
Department:
Institution:
Article Title:
Signature:  Date:

Please submit a signed and dated copy of this license by one of the following three methods:

- 1) Upload a scanned copy of the document as a pdf on the JoVE submission site;
- 2) Fax the document to +1.866.381.2236;
- 3) Mail the document to JoVE / Attn: JoVE Editorial / 1 Alewife Center #200 / Cambridge, MA 02139

For questions, please email submissions@jove.com or call +1.617.945.9051

Editorial comments:

Changes to be made by the Author(s) regarding the manuscript:

1. Please take this opportunity to thoroughly proofread the manuscript to ensure that there are no spelling or grammar issues. The JoVE editor will not copy-edit your manuscript and any errors in the submitted revision may be present in the published version.
2. Please provide figures with higher resolution if possible.
3. Figure 2C: Please define error bars in the figure legend.
4. Figure 3: Please change ml to mL.
5. Figure 6B and Figure 8C: Please include it as a table and upload it separately in the form of an .xls or .xlsx file.
6. Figures 8: Please line up panels A and B better.
7. JoVE cannot publish manuscripts containing commercial language. This includes trademark symbols (™), registered symbols (®), and company names before an instrument or reagent. Please remove all commercial language from your manuscript and use generic terms instead. All commercial products should be sufficiently referenced in the Table of Materials and Reagents. For example: Agilent RNA 6000 Pico Kit, Agilent 2100 Bioanalyzer, Illumina TruSeq, Pippin Prep, KAPA, Bowtie, etc.
8. Please adjust the numbering of the Protocol to follow the JoVE Instructions for Authors. For example, 1 should be followed by 1.1 and then 1.1.1 and 1.1.2 if necessary. Please refrain from using bullets, dashes, or indentations.

Thank you, for points 1- 7 we have reworked the manuscripts, figures and tables as you have suggested.

9. Please revise the protocol (107-122, 125-127, 135-142, etc.) to contain only action items that direct the reader to do something (e.g., “Do this,” “Ensure that,” etc.). The actions should be described in the imperative tense in complete sentences wherever possible. Avoid usage of phrases such as “could be,” “should be,” and “would be” throughout the Protocol. Any text that cannot be written in the imperative tense may be added as a “Note.” Please include all safety procedures and use of hoods, etc. Please move the discussion about the protocol to the Discussion.

These sections have also now been rewritten accordingly.

10. Please add more details to your protocol steps. There should be enough detail in each step to supplement the actions seen in the video so that viewers can easily replicate the protocol. Please ensure you answer the “how” question, i.e., how is the step performed? Alternatively, add references to published material specifying how to perform the protocol action.

A more detailed detailed library construction protocol (which is the crux of this protocol) has now been added. (Section 5 on page 5)

11. Please provide composition of MSC media, ExRNA collecting media, etc. If purchased, please cite the Materials Table.

The Materials table has been cited. It now reads (line 87-88): “Preparation: Mesenchymal Stem Cell Growth Medium (MSC media) is prepared beforehand as indicated in the Materials table.”

12. Line 95: What is the concentration of trypsin?

This has now been added: 0.05% Trypsin-EDTA (line 100 of the new draft)

13. Line 102: What container is used?

T175 flasks were used and this is now added (line 106-109) .

14. Line 123: How to dry the inside of the tube?

How the inside of the tube was dried is now revised (line 130-133): "Remove the supernatant, dry the inside of the tube by inverting the tube on absorbent paper and use small pieces of absorbent paper to remove the liquid inside the tube without touching the bottom of the tube, and resuspend the pellet in 200 µl of PBS by vortexing for 30 s and pipetting up and down 20 times."

15. Line 162: Please specify what samples (i.e., from which this step) are used.

Now amended (line 169): "Thaw samples from step 2.9 on ice."

16. Line 164: It is unclear. From where is the RNA eluted?

Now amended (line 171): "Elute the RNA from the column provided in the RNA isolation kit in 100 µl of RNase free water."

17. For steps that are using a commercial kit (lines 172-174, 178-180, 191-195, 202-203, etc.), please ensure that the protocol steps have sufficient details to replicate.

These sections have been revised accordingly. The Library Construction sections (Section 5) have been fully revised in detail.

18. Please include single-line spaces between all paragraphs, headings, steps, etc.

19. After you have made all the recommended changes to your protocol (listed above), please highlight 2.75 pages or less of the Protocol (including headings and spacing) that identifies the essential steps of the protocol for the video, i.e., the steps that should be visualized to tell the most cohesive story of the Protocol.

20. Please highlight complete sentences (not parts of sentences). Please ensure that the highlighted part of the step includes at least one action that is written in imperative tense.

21. Please include all relevant details that are required to perform the step in the highlighting. For example: If step 2.5 is highlighted for filming and the details of how to perform the step are given in steps 2.5.1 and 2.5.2, then the sub-steps where the details are provided must be highlighted.

22. As we are a methods journal, please revise the Discussion to explicitly cover the following in detail in 3-6 paragraphs with citations: **done**

- a) Critical steps within the protocol
- b) Any modifications and troubleshooting of the technique
- c) Any limitations of the technique
- d) The significance with respect to existing methods
- e) Any future applications of the technique

23. References: Please do not abbreviate journal titles.

Points 18-23 have been revised accordingly.

Reviewers' comments:

Reviewer #1:

Manuscript Summary:

Dear author,


The manuscript reported the protocol details a complete guide to harvesting exRNAs from culture media, optimizing small RNA raw library data. This protocol provides a specific exosomal extraction process that can reduce the difficulty of exosomal acquisition. Although the authors presented some confidential results about the records for this study, there are several serious questions raised as followed:

Major Concerns:

1.Line 108-109: "EV collecting media is normal MSC media, but prepared with EV-depleted FBS. "Whether there is FBS in EV collecting media? How"EV - depleted FBS"did not show in this article. Whether the medium treated by this method has any effect on cells growth.

Thank you for your comment. The EV-depleted FBS was bought from a company (refer to the Materials list). Since cells were grown in normal media (with normal FBS) we did not assess whether EV-free media affected proliferation or growth. The main reason is because the EV-free media mainly served as a medium for EV collection, for EV collection, meanwhile the normal media was used for both proliferation and differentiation.

2.Line 148: "Replenish the osteoblastic differentiation media once every 2-3 days ." This concept is too vague, please give the specific shape of the cells when you need to change the media,or quote the relevant literature to explain the state of the cell at this time.



Previous studies by our lab demonstrated that replacing the osteogenic differentiation medium every 2-3 days promotes osteoblastic differentiation (see references below) and the figure above.

<https://doi.org/10.1002/stem.1615>

<https://doi.org/10.1016/j.ymthe.2017.11.018>

3.Line162: "Remove the samples from -80°C and thaw on ice. "Is the freshly obtained exosomes treated in the article? Is there a comparison the efficiency of the two methods? Have other literatures tested for two different environmental efficiencies?


The freshly obtained EVs were not treated in the article. The main reason they are stored at -80°C is for optimal storage of the RNA for downstream usage. Storage conditions that evaluated the temperature effects on exosomes have been previously described (links to the references are supplied below).

<https://link.springer.com/article/10.1007%2Fs12257-015-0781-x>

<https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4275651/>

4. Figure 2: The morphology of undifferentiated BMSCs (figure 2A) and BMSCs differentiated for 7 days (figure 2B) look similar. Pictures must be taken at higher magnification. A count of undifferentiated, mixed and differentiated colonies as it is usually done could help in understanding the level of differentiation observed in the cell populations.

The level of differentiation was previously shown by means of Alizarin Red S staining, which is commonly used for the detection of *in vitro* differentiated BMSCs. The results were not included in this paper, however, the extent of differentiation (amount of red staining signifying the amount of calcium deposition from osteogenesis) is visible in the figure below.



Minor Concerns:

5. Please provide the manufacturer and item number of the kit in the article.

All manufacturer items and numbers are in the Materials list that was submitted along with the manuscript. Jove specifically asked for us to leave out company names and trademarks.

Reviewer #2:

Manuscript Summary:

The manuscript describes a method of measuring the RNA profile of extracellular vesicles from cultured MSC. The authors describe the culture of cells, the collection of media, the isolation of EVs from the medium, the isolation of RNA from the EVs, cDNA preparation, and a bioinformatic pipeline for measuring the library, all with quality checkpoints described. The protocol is concise but seemingly relatively complete. A few minor concerns exist.

Major Concerns:
Figures are unreadable.

My apologies, the system only allows for very small file sizes. We have reworked everything now.

Please discuss why so many bacterial reads are appearing in the preps. Since these are ostensibly clean cultured cell samples, this is highly unexpected.

Thank you for your comment. We too have been perturbed by this puzzling finding. We have discussed these findings in the discussion section: "One of the reasons for these contaminants is that bacteria overlap in size with extracellular complexes or EVs, and hence co-purify during the ultracentrifugation step. Previous publications have identified widespread contamination of certain bacteria in culture media which remain undetected under normal cell lab procedures. To date, this problem has largely been ignored but should be taken into account when purifying and analyzing exRNAs."

Minor Concerns:

Step 2.5: The authors recommend four centrifugation steps. Many protocols call for only three steps. Often time, EV isolation is some variation of low speed, medium speed, high speed. Authors may want to add a note as to why they recommend two medium speed steps.

The protocol we used was previously published in <https://doi.org/10.3402/jev.v3.25011>. We opted for this method because two medium steps of centrifugation ensured that cells and cellular debris was fully eliminated.

2.7: Authors tell the reader to "dry" the centrifuge tubes. The reviewer agrees that this is important, but they may want to add some detail about how they recommend drying. E.g., vacuum, air drying, etc. This is a nontrivial step and could help to avoid contaminants. Also resuspending is important. Tell the reader how many times they may expect to have to triturate their sample, as often the pellet is too small to see with the naked eye.

Thank you for your comment. We have revised this now and it now reads, "Remove the supernatant, dry the inside of the tube by inverting the tube on absorbent paper and use small pieces of absorbent paper to remove the liquid inside the tube without touching the bottom of the tube, and resuspend the pellet in 200 μ l of PBS by vortexing for 30 s and pipetting up and down 20 times."

4.2: Please recommend to readers which small RNA isolation kits the authors have experience with, along with pros/cons if available.

Thank you for your comment. Unfortunately, we haven't performed systematic experiments to demonstrate the efficiency of different small RNA isolation kits. The main takeaway from this paper is to know that when some results differ from recommended protocols, and that the reason is because the samples are not conventional samples (they are EVs).

6.3: Some explanation of this formula would be helpful.

"Normalize miRNA expression using the following formula: (miRNA counts / the total counts of all mapped miRNAs) * 10^6 "

This formula is a method to quantify the relative expression of miRNAs in a sample by representing it as the number of reads per million.

If you would like your personal information to be removed from the database, please contact the publication office.